G1 Ther­a­peu­tics aban­dons PhI­II col­orec­tal can­cer tri­al af­ter dis­ap­point­ing over­all re­sponse rates

On­col­o­gy-fo­cused G1 Ther­a­peu­tics aban­doned a Phase III tri­al test­ing tri­laci­clib in com­bi­na­tion with oth­er drugs in pa­tients with metasta­t­ic col­orec­tal can­cer af­ter dis­ap­point­ing re­sults. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER